Last mentioned: Mar 6, 2026
Potential Extension
Aptorum may apply for a second 180-day period if compliance is not met but criteria are satisfied.
Initial Compliance Deadline
End of the first 180-day grace period to regain a $1.00 closing bid price.
Deficiency Notice Received
Nasdaq notifies Aptorum of non-compliance with the $1.00 minimum bid price rule.
Aptorum Group Limited (APM) has received a formal deficiency notice from Nasdaq for failing to maintain the $1.00 minimum bid price required for continued listing. The company now enters a critical 180-day window to regain compliance, highlighting the ongoing financial pressures facing small-cap clinical-stage biotech firms.
This page surfaces every story mentioning Aptorum Group Limited across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where Aptorum Group Limited was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |